Lifshitz Law Firm is investigating GeneDx Holdings Corp. for potential breaches of fiduciary duties by its directors and officers. This follows several similar investigations alleging the company misled investors.
The scrutiny stems from first-quarter financial results released on May 4, 2026. GeneDx missed performance targets for its exome and genome product lines during this period.
Management significantly reduced its 2026 revenue guidance. The company also disclosed lower-than-expected reimbursement rates and a goodwill impairment charge from a recent acquisition. These disclosures resulted in a sharp decline in the company's share price.